LOGIN
Oromucosal route of delivering cannabis based medicine safe and effective in pain reduction
September 2018
Oromucosal route of delivering cannabis based medicine safe and effective in pain reduction
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Neurology. 2005 Sep 27;65(6):812-9Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
66 patients with central neuropathic pain due to multiple sclerosis (MS) were randomly assigned to receive either cannabis-based medicine (CBM) through oromucosal spray or placebo for 4 weeks. Participants were assessed on pain severity, sleep disturbances, the impression of change, the incidence of adverse events, cognitive abilities, mood, and MS-related disability at the beginning and end of th...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.